

# Interaction between placental efflux transporters and use of antiepileptic or antidepressant drugs during pregnancy on birth weight in the Norwegian Mother, Father and Child Cohort Study

Marta H. Hernandez<sup>1,2\*</sup>, Jacqueline M. Cohen<sup>1,3</sup>, Karoline H. Skåra<sup>1,4</sup>, Thea K. Grindstad<sup>1</sup>, Yunsung Lee<sup>1</sup>, Per Magnus<sup>1</sup>, Pål R. Njølstad<sup>5,6</sup>, Ole A. Andreassen<sup>7,8</sup>, Elizabeth C. Corfield<sup>9,10</sup>, Alexandra Havdahl<sup>9,10,11,12</sup>, Espen Molden<sup>13,14</sup>, Kari Furu<sup>1,3</sup>, Maria C. Magnus<sup>1¶</sup>, Alvaro Hernaez<sup>1,2¶</sup>

1. Centre for Fertility and Health, Norwegian Institute of Public Health, Oslo, Norway.
2. Blanquerna School of Health Sciences, University Ramon Llull, Barcelona, Spain.
3. Department of Chronic Diseases, Norwegian Institute of Public Health, Oslo, Norway.
4. Department of Community Medicine and Global Health, Institute of Health and Society, University of Oslo, Oslo, Norway.
5. Center for Diabetes Research, Department of Clinical Science, University of Bergen, Bergen, Norway
6. Children and Youth Clinic, Haukeland University Hospital, Bergen, Norway
7. Norwegian Centre for Mental Disorders Research, NORMENT, Division of Mental Health and Addiction, Oslo University Hospital, Oslo, Norway
8. Institute of Clinical Medicine, University of Oslo, Oslo, Norway
9. Center for Genetic Epidemiology and Mental Health, Norwegian Institute of Public Health, Oslo, Norway
10. Nic Waals Institute, Lovisenberg Diakonale Hospital, Oslo, Norway
11. PROMENTA Research Center, Department of Psychology, University of Oslo, Oslo, Norway

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

29 12. MRC Integrative Epidemiology Unit, University of Bristol, Bristol, United Kingdom

30 13. Center for Psychopharmacology, Diakonhjemmet Hospital, Oslo, Norway.

31 14. Section for Pharmacology and Pharmaceutical Department of Pharmacy,  
32 University of Oslo, Oslo, Norway

33

34 ¶: both authors contributed equally to this work.

35

36 **\*Corresponding author**

37 E-mail: [martahh1@blanquerna.url.edu](mailto:martahh1@blanquerna.url.edu) (MHH)

## ABSTRACT (286 words)

**Background:** Intrauterine exposure to antiseizure and antidepressant drugs is associated with adverse pregnancy outcomes, including low birth weight. Gene variants in placental efflux transporter genes may alter foetal exposure to these drugs.

**Methods:** We investigated whether genetic variants in placental efflux transporters modified the impact of maternal antiseizure and antidepressant drug use on offspring birth weight, using data from the Norwegian Mother, Father and Child Cohort Study and the Medical Birth Registry of Norway (69,828 offspring with their genotype data, 81,189 with maternal genotype data). We systematically searched for gene variants in placental efflux transporters influencing drug exposure [MDR1-*ABCB1* (7 alleles), MRP1-*ABCC1* (2), MRP2-*ABCC2* (3) and, BCRP-*ABCG2* (2)] and calculated genetic scores (sum of alleles potentially related to low transporter activity). We assessed the interaction between prenatal drug use and genetic scores on birth weight.

**Findings:** Prenatal antiseizure medication exposure was associated with lower birth weight (-95.5 grams, 95% CI -190 to -0.78). This relationship depended on the offspring's MRP2-*ABCC2* genetic score. Birth weight differences between exposed vs. unexposed were 70.3 g (95% CI -494 to 634) in the lowest genetic score category and -306 g (95% CI -361 to -31.8) in the highest (interaction *p*-value = 0.019; main variant: rs3740066). The antiseizure medication-lower birth weight association also depended on the maternal MDR1-*ABCB1* genetic score. Birth weight differences between exposed vs. unexposed were -66.8 g (95% CI -225 to 91.2) in the lowest genetic score category and -317 g (95% CI -517 to -117) in the highest (interaction *p*-value = 0.037; main variants: rs10248420 and rs2235015). Prenatal antidepressant exposure was associated with low birth weight, but no gene-drug interactions were observed.

**Conclusions:** MRP2-*ABCC2* and MDR1-*ABCB1* variants may influence prenatal antiseizure medication's impact on neonatal birth weight.

**Keywords:** antiseizure medication, birth weight, MRP2-*ABCC2*, MDR1-*ABCB1*, MoBa, MBRN.

## SUMMARY

### What is already known on this topic.

- Low birth weight increases the risk of neonatal death, morbidity, and lifelong susceptibility to various health conditions, including neurodevelopmental, cardiometabolic, respiratory, and psychiatric disorders.
- Previous studies have reported an association between maternal use of centrally acting medication during pregnancy and low birth weight in the offspring, but the underlying causes remain poorly understood.
- It is of great concern to identify strategies that can modulate foetal exposure to these medications and enable individualised, safe use since discontinuation may also increase the risk of harm to the mother.

### What this study adds.

- Our study uncovered genetic variants in both offspring (rs3740066) and mother (rs10248420 and rs2235015) linked to placental efflux transporters that modulated the association between maternal antiseizure drug use during pregnancy and the risk of low birth weight in the offspring, marking the first exploration of such interactions.
- If these findings are confirmed and information about specific drugs is incorporated, this could potentially be used in the development of personalized recommendations for pregnant women undergoing these treatments.

## INTRODUCTION

The use of medication during pregnancy must carefully balance benefits to the mother and potential harm to the offspring.<sup>1</sup> Centrally acting drugs (such as antiseizure drugs [mainly lamotrigine, 0.3% of pregnancies] and antidepressants [1.5% of pregnancies]) have been increasingly used during pregnancy.<sup>2,3</sup> However, intrauterine exposure to these medications may be associated with adverse pregnancy outcomes such as impaired foetal growth and reduced birth weight in offspring.<sup>4-6</sup> Furthermore, these conditions are linked to a multitude of morbidities, resulting in both immediate and long-term adverse consequences for newborns, their families, and society.<sup>7</sup> The placenta plays an essential role in substance exchange between mother and foetus (e.g., nutrients, metabolic by-products). Small, non-polar, lipophilic xenobiotics such as antiseizure drugs and antidepressants can pass through the placenta via passive diffusion.<sup>8</sup> However, several active proteins can efflux these compounds from the foetus back to the mother.<sup>9</sup> Active efflux proteins from the adenosine triphosphate-binding cassette superfamily (such as P-glycoprotein, breast cancer resistance protein, and others multidrug resistance proteins) are involved in the transplacental passage of drugs particularly affecting the passage of centrally-acting drugs and their metabolites.<sup>10,11</sup> Several antiseizure drugs and antidepressants are substrates for these transporters.<sup>12,13</sup> Efflux transporters may therefore have a foetoprotective effect by lowering the concentrations of potentially toxic drugs on the foetal side. Genetic variants in the transporters may modify their activity and could be located in the offspring or maternal genotype.<sup>14,15</sup> Little is known about the role of genetic variants in placental efflux transporters on the modulation of the association of antiseizure drugs and antidepressants during pregnancy with offspring outcomes such as low birth weight.

Our aim was to explore whether there is an interaction between the use of antiseizure drugs or antidepressants during pregnancy and genetic variants related to

115 placental efflux transporters (in P-glycoprotein, breast cancer resistance protein, and  
116 others multidrug resistance proteins) on offspring birth weight.

## MATERIALS AND METHODS

### *Study participants*

We included participants in the Norwegian Mother, Father, and Child Cohort Study (MoBa). MoBa is a prospective, population-based pregnancy cohort conducted by the Norwegian Institute of Public Health. Pregnant women and their partners were recruited across Norway between 1999-2008 at the time of routine ultrasound screening (~17<sup>th</sup> gestational week). The cohort includes approximately 114,000 children, 95,000 mothers, and 75,000 fathers.

This work used a subsample of offspring from singleton pregnancies with available information on genotype and birth weight (from version #12 of the quality-assured data files released on May 11, 2022). Genotype data was obtained from blood samples provided during pregnancy and at birth (mothers) and umbilical cord blood at birth (offspring).<sup>16</sup> A total of 238,001 samples have been genotyped in 24 genotyping batches with varying selection criteria, genotyping platforms, and genotyping centres.<sup>17</sup> Quality control, phasing, and imputation were performed using the MoBaPsychGen pipeline as previously described.<sup>17</sup>

Our work is described according to the Strengthening the Reporting of Observational studies in Epidemiology guidelines (Supplemental Table 3).<sup>18</sup>

### *Use of centrally acting drugs*

We used self-reported information on the use of centrally acting drugs from MoBa questionnaires in the 18<sup>th</sup> and 30<sup>th</sup> gestational weeks.<sup>19</sup> Specifically, women were asked whether they had epilepsy or depression, and if they answered yes, whether any medications were used to treat the condition(s). This project has no information on the specific drug(s) the woman used. Any reported use of medication(s) for epilepsy (yes/no) or depression (yes/no) were categorized and evaluated separately.

## *Birth weight*

Data on offspring birth weight in grams was obtained from the Medical Birth Registry of Norway, a national health registry which contains information about all births in Norway since 1967.<sup>20</sup>

## *Covariates*

Information on maternal age at delivery (continuous), parity (1, 2, 3,  $\geq 4$ ) and sex of the offspring (female/male) was obtained from the birth registry. Furthermore, information on maternal years of education (continuous), pre-pregnancy body mass index (continuous), having ever smoked (yes/no), and self-reported depression or epilepsy was gathered in the questionnaire administered at gestational week 18.

## *Genetic variants related to placental transporters and genetic scores.*

We performed a systematic review in PubMed, Web of Science, pharmacogenetic websites (<https://www.pharmgkb.org>) and GWAS catalog (<https://www.ebi.ac.uk/gwas/>) to identify gene variants on the adenosine triphosphate-binding cassette superfamily of placental efflux transporters (MDR1-*ABCB1*, MRP1-*ABCC1*, MRP2-*ABCC2*, and BCRP-*ABCG2*). We followed the recommendations of the Preferred Reporting Items for Systematic reviews and Meta-Analyses statement.<sup>21</sup> A detailed description of the search is available in Supplemental Materials.

After the systematic review, we only conserved genetic variants that were not in linkage disequilibrium according to linkage disequilibrium block analysis in the 1000 Genomes CEU and GBR populations (given the MoBa participants passing the post-imputation quality control cluster with these populations;  $R^2 < 0.8$ ) and with a minor allele frequency  $> 1\%$ .<sup>22</sup> Genetic scores were calculated as the sum of the number of risk alleles for all genetic variants related to each transporter in a participant. The genetic score was represented in the results as a genetic score if the number of score values were  $\leq 5$ . Otherwise, we represented them in quartiles. We considered a risk allele to be



the allele associated with any of these five theoretical situations potentially related to an increased exposure of the drug to the foetus: decreased function of the transporter, declined expression of the transporter, non-resistance to the treatment, higher concentrations of the drug, or more adverse effects. Information related to the studies is available in Supplemental Table 2.

### *Ethical approval*

The MoBa study is conducted according to the Declaration of Helsinki for medical research involving human subjects. The establishment of MoBa and initial data collection was based on a license from the Norwegian Data Protection Agency. It is now based on regulations related to the Norwegian Health Registry Act. Participants provided written informed consent before joining the cohort. This project was approved by the Regional Committee for Medical and Health Research Ethics of South/East Norway (reference: 2017/1362).

### *Statistical analyses*

Normally distributed continuous variables were described by means and standard deviations, nonnormally distributed continuous variables by medians and 25<sup>th</sup>-75<sup>th</sup> percentiles, and categorical variables by proportions.

We first assessed the relationship between maternal use of centrally acting drugs during pregnancy and birth weight using multivariable linear regressions adjusted for offspring sex and maternal factors (age at delivery, years of education, pre-pregnancy body mass index, parity and having ever smoked). Clustered standard errors were computed to account for dependence among births to mothers contributing with more than one pregnancy in MoBa. To determine whether there were significant interactions between maternal prenatal use of centrally acting drugs and the genetic scores on the offspring birth weight, we applied likelihood ratio tests between nested linear regression models with and without an interaction product-term of “exposure group × genetic score”.

The nested models were further adjusted for the first twenty ancestry-informative genetic principal components and genotyping batch. We considered any interaction with a  $p$ -value for the overall interaction test  $< 0.05$  and a differential association between medication use and offspring birth weight in the two extreme categories according to the genetic score. Whether an interaction was found, we further explored interactions with the individual variants in the genetic score as sensitivity analyses using the same strategy (as these were exploratory sensitivity analyses, we here considered any interaction with a  $p$ -value  $< 0.1$ ).

Statistical analyses were performed in R Software, version 4.1.0. Our analysis code is available in GitHub:


[https://github.com/alvarohernaez/Gene\\_pschoactivedrug\\_BW\\_MoBa/](https://github.com/alvarohernaez/Gene_pschoactivedrug_BW_MoBa/).

## RESULTS

### *Study population*

In our study, we included 69,828 singleton pregnancies with offspring genotype information and offspring birth weight, and 81,189 singleton pregnancies with maternal genotype data and offspring birth weight (Figure 1). Mean birth weight was 3,639 grams (SD 522). A total of 174 children (0.25%) were exposed to maternal use of antiseizure drugs during pregnancy and 766 (1.10%) to antidepressants. Women using centrally acting drugs were younger (only for antiseizure drugs), had lower educational attainment, and were more likely to have ever smoked (Table 1).

**Figure 1.** Flow chart of study participants.



227 **Table 1.** Baseline characteristics of mothers with offspring genotype information.

228

	<b>Antiseizure drugs</b>		<b>Antidepressants</b>	
	<b>Exposed (<i>n</i> = 174)</b>	<b>Unexposed (<i>n</i> = 69,654)</b>	<b>Exposed (<i>n</i> = 766)</b>	<b>Unexposed (<i>n</i> = 69,062)</b>
Age at delivery (years), mean ± SD	29.1 ± 4.83	30.2 ± 4.52	30.2 ± 5.07	30.2 ± 4.51
Education years, mean ± SD	15.9 ± 3.64	17.1 ± 3.30	16.2 ± 3.63	17.2 ± 3.30
Pre-pregnancy body mass index (kg/m <sup>2</sup> ), median (25 <sup>th</sup> -75 <sup>th</sup> percentiles)	23.3 (21.6-26.4)	23.3 (21.1-25.9)	23.2 (21.1-26.6)	23.1 (21.1-25.9)
Having ever smoked, <i>n</i> (%)	107 (61.8%)	34,310 (50.0%)	510 (67.4%)	33,907 (49.9%)
Previous number of deliveries:				
0, <i>n</i> (%)	64 (36.8%)	23,589 (33.9%)	261 (34.1%)	23,343 (33.9%)
1, <i>n</i> (%)	42 (24.1%)	22,342 (32.1%)	223 (29.1%)	22,113 (32.1%)
2, <i>n</i> (%)	44 (25.3%)	13,697 (19.7%)	156 (20.4%)	13,547 (19.7%)
3, <i>n</i> (%)	15 (8.62%)	6,118 (8.78%)	72 (9.40%)	6,045 (8.77%)

≥4, <i>n</i> (%)	9 (5.17%)	3,908 (5.61%)	54 (7.05%)	3,851 (5.59%)
Offspring birth weight, mean ± SD	3,516 ± 603	3,639 ± 522	3,574 ± 512	3,640 ± 522
Biological sex of the offspring:				
Female, <i>n</i> (%)	84 (48.3%)	35,549 (51.0%)	366 (47.8%)	35,267 (51.1%)
Male, <i>n</i> (%)	90 (51.7%)	34,105 (49.0%)	400 (52.2%)	33,795 (48.9%)

229

## *Search of genetic variants on placental transporters*

The systematic search identified 26 genetic variants in the placental transporter genes associated with differences in antiseizure drugs and/or antidepressant outcomes (Supplemental Figure 1), of which 14 were independent and available in the MoBa genotype database (Supplemental Table 1). Seven variants were found for MDR1-*ABCB1*, two for MRP1-*ABCC1*, three for MRP2-*ABCC2*, and two for BCRP-*ABCG2*. We used these genetic variants to calculate risk scores. The ranges of values for the four genetic scores calculated were: 0 to 11 (MDR1-*ABCB1*; we presented the stratified associations according to quartiles), 0 to 4 (MRP1-*ABCC1*), 2 to 6 (MRP2-*ABCC2*), and 0 to 4 (BCRP-*ABCG2*).

## *Interaction between genetic variants of placental transporters and exposure to antiseizure drugs during pregnancy on birth weight*


Antiseizure medication use during pregnancy was associated with lower birth weight (-95.5 g, 95% confidence interval [CI] -190 to -0.78). Greater values of the MRP2-*ABCC2* genetic score in the offspring were associated with lower birth weight in offspring of mothers who used antiseizure drugs during pregnancy. The difference in birth weight between exposed vs. unexposed was 70.3 g (95% CI -494 to 634) in the lowest genetic score category (2 risk alleles) and -306 g (95% CI -361 to -31.8) in the highest (6 risk alleles) ( $p$ -value for interaction = 0.019; Figure 2). The variant with the strongest evidence of an interaction in the sensitivity analyses of the MRP2-*ABCC2* genetic score was rs3740066 ( $p$ -value for interaction = 0.023; Supplemental Figure 2).

Greater values of the MDRP1-*ABCB1* genetic score in the mother were also linked to lower birth weight among offspring of mothers who used antiseizure drugs during pregnancy. The difference in birth weight between exposed vs. unexposed were -66.8 g (95% CI -225 to 91.2) in the lowest genetic score category (first quartile) and -317 g (95% CI -517 to -117) in the highest (fourth quartile) ( $p$ -value for interaction = 0.037; Figure 3). Variants rs10248420 and rs2235015 included in the MDRP1-*ABCB1*

258 genetic score had some evidence of an interaction in the sensitivity analyses ( $p$ -values  
259 for interactions = 0.042 and 0.058, respectively; Supplemental Figure 3).

260 **Figure 2.** Differences in birth weight associated with pregnancy exposure to antiseizure medication due to the genetic scores for placental  
 261 transporters in the offspring.


262





263 **Figure 3.** Differences in birth weight associated with pregnancy exposure of antiseizure medication due to the genetic scores for placental  
 264 transporters in the mother.

265



266 *Interaction between genetic variants of placental transporters and exposure to antidepressants*  
 267 *during pregnancy on birth weight*  
 268 Use of antidepressant drugs during pregnancy was associated with lower birth weight (-60.5  
 269 g, 95% CI -97.6 to -23.3). However, we observed no interactions between prenatal use of  
 270 antidepressants and any genetic score of placental efflux transporters (in offspring or mothers)  
 271 on birth weight in the offspring (Supplemental Figures 4 and 5).

## DISCUSSION

In this large population-based study, involving offspring of mothers who used antiseizure medication during pregnancy, a high genetic score for MRP2-*ABCC2* in the offspring and MDR1-*ABCB1* in the mother, suggesting a greater exposure to these drugs, was associated with lower birth weight in the offspring.

MDR1-*ABCB1* and MRP2-*ABCC2* are the only transporters located in the apical membrane of the trophoblast (maternal side) and their function is to return xenobiotics to maternal circulation.<sup>23</sup> Thus, it seems plausible that genetic variants linked to lower transporter activity are associated with higher foetal exposure and greater toxicity of antiseizure drugs. In addition, the main variant in the interaction between the MRP2-*ABCC2* genetic score and prenatal antiseizure drug use (rs3740066) has been previously linked to a poorer response to antiseizure medication<sup>24</sup> and a higher risk of other adverse events during pregnancy (intrahepatic cholestasis of pregnancy).<sup>25</sup> The differences in the interactions found within genetic variants in the offspring (MRP2-*ABCC2*) and maternal genome (MDR1-*ABCB1*) can be explained by physiological changes in the placenta structure. Early in pregnancy, the separation between the maternal circulation and the foetal circulation by the trophoblasts villous barrier is 50-100  $\mu\text{m}$  (second month). It becomes progressively thinner as the pregnancy proceeds (only 4-5  $\mu\text{m}$  at term).<sup>26</sup> In addition, the total placenta surface area increases from about 5  $\text{m}^2$  at 28 weeks of gestation to 12  $\text{m}^2$  at term. Thus, passive diffusion of medications increases with gestational age, which means that medication can reach the foetal circulation more easily later in pregnancy.<sup>26</sup> At the same time, the expression of MRP2-*ABCC2* increases with advancing gestational age, whereas the expression of MDR1-*ABCB1* declines.<sup>27,28</sup> As a consequence of all these phenomena, the presence of risk alleles for MRP2-*ABCC2* may play a more significant role in determining the offspring's exposure. However, an alternative hypothesis could also explain our findings. A greater foetal exposure to medication due to lower activity of the efflux transporters may also be linked to lower medication levels in the mother and a poorer control of the disease. Greater disease effects in mothers may be

associated with alternative mechanisms that may also explain an increased risk of low birth weight in the offspring.

There could be several reasons for the lack of gene-drug interactions with antidepressants. First, the association between exposure to antidepressants during pregnancy and birth weight is of a smaller magnitude in our data, which can make the search of gene-drug interactions more challenging. Second, the accuracy of our data regarding the usage of antidepressants may be less precise, as women may have varying criteria for identifying such treatments. This discrepancy may not be present regarding antiseizure drugs. Finally, a larger proportion of women may discontinue the use of antidepressants during pregnancy compared to antiseizure medications.<sup>29</sup>

Our study has some limitations. First, due to the unavailability of information on the specific drug utilized, we conducted our analysis based on aggregated drug groups. Although the main medications in each group show similar pharmacodynamic behaviour and their usage during pregnancy reduces the number of medications under consideration,<sup>3</sup> this may interfere with our findings because there may be variations in the medication groups' interactions due to differences in transporter affinity or dose-dependent effects.<sup>26,30</sup> Second, due to the lack of a genome-wide association study showing which genetic variants are associated with high or low activity of efflux transporters, we calculated risk scores using studies on genetic variants indirectly related to high or low activity (e.g., treatment resistance, treatment efficacy, presence of adverse effects). Third, the interactions found in our data are only suggestive and our findings require replication in independent populations to confirm their validity. Finally, the characteristics of our participants (individuals of northern European ancestry with moderate-high socioeconomic status) limit our capacity to generalize our conclusions to other populations.

## CONCLUSIONS

In summary, genetic variants in MRP2-*ABCC2* and MDR1-*ABCB1* placental transporters may modulate the association between prenatal exposure to antiseizure drugs and low birth weight in the offspring. To the best of our knowledge, this is the largest gene-drug interaction study on offspring birth weight to date and it was performed in a well-characterized population with genome-wide genotype information. If our findings are confirmed, particularly in studies in which we know exactly which drug the mothers have used during pregnancy, the assessment of these genetic variants may be implemented in clinical settings to support safer use of antiseizure drugs during pregnancy.

## DATA AVAILABILITY STATEMENT

Consent given by the participants does not open for storage of data on an individual level in repositories or journals. Researchers who want access to datasets for replication should apply to [datatilgang@fhi.no](mailto:datatilgang@fhi.no). Access to datasets requires approval from the Regional Committee for Medical and Health Research Ethics in Norway and an agreement with MoBa.

## ACKNOWLEDGMENTS

The MoBa Cohort Study is supported by the Norwegian Ministry of Health and Care Services and the Ministry of Education and Research. We thank all the participating families in Norway who take part in this ongoing cohort study, and those who contributed to the recruitment and the infrastructure of the cohort.

We thank the Norwegian Institute of Public Health for generating high-quality genomic data. This research is part of the HARVEST collaboration, supported by the Research Council of Norway (project reference: #229624). We also thank the NORMENT Centre for providing genotype data, funded by the Research Council of Norway (project reference: #223273), South East Norway Health Authority, and Stiftelsen Kristian Gerhard Jebsen. We further thank the Center for Diabetes Research (University of Bergen) for providing genotype data funded by the European Research Council Advanced Grant project SELECTIONPREDISPOSED, Stiftelsen Kristian Gerhard Jebsen, the Trond Mohn Foundation, the Research Council of Norway, the Novo Nordisk Foundation, the University of Bergen, and the Western Norway Health Authority.

This work was performed on the TSD (Tjeneste for Sensitive Data) facilities, owned by the University of Oslo, operated, and developed by the TSD service group at the University of Oslo, IT-Department ([tsd-drift@usit.uio.no](mailto:tsd-drift@usit.uio.no)).

This paper does not necessarily reflect the position or policy of the Norwegian Research Council.

## FUNDING

The MoBa Cohort Study is supported by the Norwegian Ministry of Health and Care Services and the Norwegian Ministry of Education and Research. This project received funding from the European Research Council under the European Union's Horizon 2020 research and innovation program (grant agreement No 947684). This work was also partly supported by the Research Council of Norway through its Centres of Excellence funding scheme, project number 262700 and 223273, and the project "Women's fertility – an essential component of health and well-being", number 320656, and co-funded by the European Research Council (grant agreement No 101071773). M.H.H. was supported by the fellowship "*Estancias de movilidad Jose Castillejo dentro del Programa Estatal de Promoción del Talento y su empleabilidad, en el marco del Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020*", from the Spanish government. P.R.N. was supported by the European Research Council (grant agreement No 293574), the Novo Nordic Foundation (#NNF19OC0054741) and the Trond Mohn Foundation (PRECISE-DIA). E.C. and A.Havdahl were supported by the Research Council of Norway (274611) and the South-Eastern Norway Regional Health Authority (project numbers 2020022, 2021045). O.A.A. was supported by the European Research Council (grant agreement No 964874) and the Research Council of Norway (300309, 273291). The funders had no role in the study design; the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the article for publication. Views and opinions expressed in this paper are those of the authors only and do not necessarily reflect those of the funders. Neither the European Union nor the granting authority can be held responsible for them.

## CONFLICTS OF INTEREST

O.A.A. is a consultant for cortechs.ai and has received speaker's honorarium from Janssen, Lundbeck, and Sunovion unrelated to the current work. The rest of the authors declare that no competing interests exist.

## **AUTHORS' CONTRIBUTION**

M.H.H. conceived and designed the study, was responsible for data curation, formal analyses, data interpretation, and drafting the article. J.M.C. critically revised the article and contributed to interpretation of the data. K.H.S. provided support in data analysis, software use, and visualization of results, and critically revised the article. T.K.W.G. was involved in the interpretation of data and critically revised the article. Y.L. contributed to data acquisition and critically revised the article. P.M. contributed to data acquisition and critically revised the article. P.R.N. contributed to data acquisition and critically revised the article. O.A.A. contributed to data acquisition and critically revised the article. E.C. contributed to data acquisition and critically revised the article. A.Havdahl contributed to data acquisition and critically revised the article. E. Molden critically revised the article. S.E.H. contributed to data acquisition, obtained funding, and critically revised the article. K.F. provided support in data analysis and critically revised the article. M.C.M. and A.Hernaez coordinated the project, contributed to data interpretation, and critically revised the article. M.H.H. and A.Hernaez are the guarantors of this study, accept full responsibility for the work and the conduct of the study, had access to the data, and controlled the decision to publish.



## REFERENCES

1. Benevent J, Montastruc F, Damase-Michel C. The importance of pharmacoepidemiology in pregnancy-implications for safety. *Expert Opin Drug Saf.* 2017;16: 1181–1190. doi:10.1080/14740338.2017.1363177
2. Molenaar NM, Bais B, Lambregtse-van den Berg MP, Mulder CL, Howell EA, Fox NS, et al. The international prevalence of antidepressant use before, during, and after pregnancy: A systematic review and meta-analysis of timing, type of prescriptions and geographical variability. *J Affect Disord.* 2020;264: 82–89. doi:10.1016/j.jad.2019.12.014
3. Cohen JM, Cesta CE, Furu K, Einarsdóttir K, Gissler M, Havard A, et al. Prevalence trends and individual patterns of antiepileptic drug use in pregnancy 2006-2016: A study in the five Nordic countries, United States, and Australia. *Pharmacoepidemiol Drug Saf.* 2020;29: 913–922. doi:10.1002/pds.5035
4. Margulis AV, Hernandez-Diaz S, McElrath T, Rothman KJ, Plana E, Almqvist C, et al. Relation of in-utero exposure to antiepileptic drugs to pregnancy duration and size at birth. *PLoS One.* 2019;14: e0214180. doi:10.1371/journal.pone.0214180
5. Veiby G, Daltveit AK, Engelsen BA, Gilhus NE. Fetal growth restriction and birth defects with newer and older antiepileptic drugs during pregnancy. *J Neurol.* 2014;261: 579–588. doi:10.1007/s00415-013-7239-x
6. Wartko PD, Weiss NS, Enquobahrie DA, Chan KCG, Stephenson-Famy A, Mueller BA, et al. Association of antidepressant continuation in pregnancy and infant birth weight. *J Clin Psychopharmacol.* 2021; Publish Ahead of Print: 403. doi:10.1097/jcp.0000000000001410
7. Ashorn P, Ashorn U, Muthiani Y, Aboubaker S, Askari S, Bahl R, et al. Small vulnerable newborns—big potential for impact. *Lancet.* 2023;401: 1692–1706. doi:10.1016/s0140-6736(23)00354-9
8. Evseenko D, Paxton JW, Keelan JA. Active transport across the human placenta: impact on drug efficacy and toxicity. *Expert Opin Drug Metab Toxicol.* 2006;2: 51–69. doi:10.1517/17425255.2.1.51

9. Wang J-S, Newport DJ, Stowe ZN, Donovan JL, Pennell PB, DeVane CL. The emerging importance of transporter proteins in the psychopharmacological treatment of the pregnant patient. *Drug Metab Rev.* 2007;39: 723–746. doi:10.1080/03602530701690390
10. Joshi AA, Vaidya SS, St-Pierre MV, Mikheev AM, Desino KE, Nyandeger AN, et al. Placental ABC transporters: Biological impact and pharmaceutical significance. *Pharm Res.* 2016;33: 2847–2878. doi:10.1007/s11095-016-2028-8
11. Syme MR, Paxton JW, Keelan JA. Drug transfer and metabolism by the human placenta. *Clin Pharmacokinet.* 2004;43: 487–514. doi:10.2165/00003088-200443080-00001
12. Wolking S, Schaeffeler E, Lerche H, Schwab M, Nies AT. Impact of genetic polymorphisms of ABCB1 (MDR1, P-glycoprotein) on drug disposition and potential clinical implications: Update of the literature. *Clin Pharmacokinet.* 2015;54: 709–735. doi:10.1007/s40262-015-0267-1
13. Goetzl L, Darbinian N, Merabova N, Devane LC, Ramamoorthy S. Gestational age variation in human placental drug transporters. *Front Pharmacol.* 2022;13. doi:10.3389/fphar.2022.837694
14. Daud ANA, Bergman JEH, Bakker MK, Wang H, de Walle HEK, Plösch T, et al. Pharmacogenetics of drug-induced birth defects: the role of polymorphisms of placental transporter proteins. *Pharmacogenomics.* 2014;15: 1029–1041. doi:10.2217/pgs.14.62
15. Ewing G, Tatarchuk Y, Appleby D, Schwartz N, Kim D. Placental transfer of antidepressant medications: Implications for postnatal adaptation syndrome. *Clin Pharmacokinet.* 2015;54: 359–370. doi:10.1007/s40262-014-0233-3
16. Paltiel L, Haugan A, Skjerden T, et al. The biobank of the Norwegian Mother and Child Cohort Study—present status. *Norsk Epidemiologi.* 2014;24: 29–35. Available: <https://www.ntnu.no/ojs/index.php/norepid/article/view/1755/1752>
17. Corfield EC, Frei O, Shadrin AA, Rahman Z, Lin A, Athanasiu L, et al. The Norwegian Mother, Father, and Child cohort study (MoBa) genotyping data resource: MoBaPsychGen pipeline v.1. *bioRxiv.* 2022. p. 2022.06.23.496289. doi:10.1101/2022.06.23.496289

18. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. *J Clin Epidemiol.* 2008;61: 344–349. doi:10.1016/j.jclinepi.2007.11.008
19. Magnus P, Birke C, Vejrup K, Haugan A, Alsaker E, Daltveit AK, et al. Cohort profile update: The Norwegian mother and child cohort study (MoBa). *Int J Epidemiol.* 2016;45: 382–388. doi:10.1093/ije/dyw029
20. Irgens LM. The Medical Birth Registry of Norway. Epidemiological research and surveillance throughout 30 years: Thirty years' birth registration. *Acta Obstet Gynecol Scand.* 2000;79: 435–439. doi:10.1034/j.1600-0412.2000.079006435.x
21. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *BMJ.* 2021;372: n71. doi:10.1136/bmj.n71
22. Machiela MJ, Chanock SJ. LDlink: a web-based application for exploring population-specific haplotype structure and linking correlated alleles of possible functional variants. *Bioinformatics.* 2015;31: 3555–3557. doi:10.1093/bioinformatics/btv402
23. Smit JW, Huisman MT, van Tellingen O, Wiltshire HR, Schinkel AH. Absence or pharmacological blocking of placental P-glycoprotein profoundly increases fetal drug exposure. *J Clin Invest.* 11 1999;104: 1441–1447. doi:10.1172/jci7963
24. Qu J, Zhou B-T, Yin J-Y, Xu X-J, Zhao Y-C, Lei G-H, et al. ABCC2 polymorphisms and haplotype are associated with drug resistance in Chinese epileptic patients: ABCC2 polymorphisms and epilepsy drug resistance. *CNS Neurosci Ther.* 2012;18: 647–651. doi:10.1111/j.1755-5949.2012.00336.x
25. Sookoian S, Castaño G, Burgueño A, Gianotti TF, Pirola CJ. Association of the multidrug-resistance-associated protein gene (ABCC2) variants with intrahepatic cholestasis of pregnancy. *J Hepatol.* 2008;48: 125–132. doi:10.1016/j.jhep.2007.08.015
26. Al-Enazy S, Ali S, Albekairi N, El-Tawil M, Rytting E. Placental control of drug delivery. *Adv Drug Deliv Rev.* 2017;116: 63–72. doi:10.1016/j.addr.2016.08.002

27. Meyer zu Schwabedissen HE, Jedlitschky G, Gratz M, Haenisch S, Linnemann K, Fusch C, et al. Variable expression of mrp2 (abcc2) in human placenta: Influence of gestational age and cellular differentiation. *Drug Metab Dispos.* 2005;33: 896–904. doi:10.1124/dmd.104.003335
28. Sun M, Kingdom J, Baczyk D, Lye SJ, Matthews SG, Gibb W. Expression of the multidrug resistance P-glycoprotein, (ABCB1 glycoprotein) in the human placenta decreases with advancing gestation. *Placenta.* 2006;27: 602–609. doi:10.1016/j.placenta.2005.05.007
29. Cohen JM, Selmer R, Furu K, Karlstad Ø. Interrupted time series analysis to assess changes in prescription filling around conception and implications for exposure misclassification. *Pharmacoepidemiol Drug Saf.* 2020;29: 745–749. doi:10.1002/pds.4974
30. Staud F, Cervený L, Ceckova M. Pharmacotherapy in pregnancy; effect of ABC and SLC transporters on drug transport across the placenta and fetal drug exposure. *J Drug Target.* 2012;20: 736–763. doi:10.3109/1061186x.2012.716847

## SUPPORTING INFORMATION

### TABLE OF CONTENTS

<b><u>SUPPLEMENTAL MATERIALS</u></b>	30
<b><u>Search strategy of genetic variants</u></b>	30
<b><u>SUPPLEMENTAL TABLES</u></b>	31
<b><u>Supplemental Table 1. Expected risk allele for birth weight in efflux transporters</u></b>	31
<b><u>Supplemental Table 2. The articles detail the development of the expected risk allele for the transporter score</u></b>	32
<b><u>Supplemental Table 3. STROBE checklist for cohort studies</u></b>	35
<b><u>SUPPLEMENTAL RESULTS</u></b>	36
<b><u>Supplemental Figure 1. Flow chart of the systematic literature review of genetic variants on placental efflux transporters</u></b>	36
<b><u>Supplemental Figure 2. Differences in birth weight associated with pregnancy use of antiseizure drugs due to <i>ABCC2</i> individual genetic variants in the offspring</u></b>	37
<b><u>Supplemental Figure 3. Differences in birth weight associated with pregnancy use of antiseizure drugs due to <i>ABCB1</i> individual genetic variants in the mother</u></b>	38
<b><u>Supplemental Figure 4. Differences in birth weight associated with pregnancy use of antidepressant medication and placental transporter genetic scores in the offspring</u></b>	39
<b><u>Supplemental Figure 5. Differences in birth weight associated with pregnancy use of antidepressant medication and placental transporter genetic scores in the mother</u></b>	40
<b><u>SUPPLEMENTAL REFERENCES</u></b>	41

## SUPPLEMENTAL MATERIALS

### Search strategy of genetic variants

All studies that examined the association between the placental transporters of interest and epilepsy or depression were researched. We systematically searched PubMed, Web of Science, pharmacogenetic websites (<https://www.pharmgkb.org>) and GWAS catalog (<https://www.ebi.ac.uk/gwas/home>). All databases were searched using the Boolean method with the following terms (1 AND 2 AND 3): 1) “antiseizure” OR “antiepilepsy” OR “anticonvulsants” OR “antidepressant” OR “benzodiazepines”; 2) “polymorphism” OR “genetic polymorphism” OR “genetic variant” OR “pharmacogenetics”; 3) “ATP binding cassette” or “ABCB1” OR “ABCC1” OR “ABCC2” OR “ABCG2” OR “ABCC5” OR “ABCC3”. In addition, the reference and discussions of all pooled articles were carefully scanned for additional publications. We excluded studies: 1) not performed in humans; 2) not published in English; 3) not published in scientific journals; and 4) focused on other drug groups.

## 540 SUPPLEMENTAL TABLES

541

### 542 Supplemental Table 1. Expected risk allele for birth weight in efflux transporters.

543

Gene	Polymorphism	Chromosome	Position	Expected risk allele for birth weight	Expected risk allele frequency in Europeans	References	Conserved after linkage disequilibrium block analysis
<i>ABCB1</i>	rs1045642	7	87138645	G	0.42	(1-9)	Yes
<i>ABCB1</i>	rs28401781	7	87148328	T	0.12	(10)	No
<i>ABCB1</i>	rs2235067	7	87149922	T	0.13	(11)	No
<i>ABCB1</i>	rs4148740	7	87152103	G	0.13	(12)	No
<i>ABCB1</i>	rs10280101	7	87153585	C	0.13	(11)	No
<i>ABCB1</i>	rs7787082	7	87157051	A	0.18	(11,13)	No
<i>ABCB1</i>	rs2032583	7	87160561	G	0.13	(11, 14-17)	No
<i>ABCB1</i>	rs2032582	7	87160618	T/A	A: 0.41 T: 0.02	(11, 15, 18-25)	No
<i>ABCB1</i>	rs4148739	7	87161049	C	0.13	(10-12)	No
<i>ABCB1</i>	rs11983225	7	87161520	C	0.13	(11)	No
<i>ABCB1</i>	rs10248420	7	87164986	G	0.18	(11, 26)	Yes
<i>ABCB1</i>	rs2235040	7	87165750	T	0.13	(11,15,16)	No
<i>ABCB1</i>	rs12720067	7	87169356	T	0.13	(11)	No
<i>ABCB1</i>	rs2032588	7	87179443	G	0.94	(27)	No, SNP not in MoBa
<i>ABCB1</i>	rs1128503	7	87179601	G	0.58	(5,12,22)	Yes
<i>ABCB1</i>	rs2235015	7	87199564	A	0.21	(11,17)	Yes
<i>ABCB1</i>	rs9282564	7	87229440	G	0.10	(28)	Yes
<i>ABCB1</i>	rs10245483	7	89637608	G	0.51	(29)	Yes
<i>ABCC1</i>	rs875740	16	16123048	C	0.35	(30)	Yes
<i>ABCC1</i>	rs212090	16	16236004	A	0.46	(31,32)	Yes
<i>ABCC2</i>	rs717620	10	101542578	C	0.79	(33-36)	Yes
<i>ABCC2</i>	rs4148386	10	101548468	G	0.44	(12)	No
<i>ABCC2</i>	rs2273697	10	101563815	G	0.80	(12, 37)	Yes
<i>ABCC2</i>	rs3740066	10	101604207	C	0.63	(12,33,38)	Yes
<i>ABCG2</i>	rs2231142	4	89052323	T	0.10	(39,40)	Yes
<i>ABCG2</i>	rs3114020	4	89083666	C	0.40	(40)	Yes

544

**Supplemental Table 2.** The articles detail the development of the expected risk allele for the transporter score.

Gene	Polymorphism	Drug	Study participants	Effect		P-value	Expected risk allele in the publication	Risk allele for birth weight	Reference
<i>ABCB1</i>	rs1045642	All antiepileptic drugs	114 drug-resistant epilepsy patients, 213 seizure-free patients and 287 controls (Taiwan)	Efficacy	The C allele and the CC genotype were associated with drug resistance relative to the T allele and the TT genotype.	0.001	T	G	1
<i>ABCB1</i>		All antiepileptic drugs	746 patients with epilepsy and 179 controls (China)	Efficacy	The TT genotype was associated with drug resistance	0.0009	G		2
<i>ABCB1</i>		All antiepileptic drugs	220 patients with epilepsy and 220 controls (India)	Efficacy	The TT genotype was associated with drug resistance relative to the CC genotype.	0.001	G		3
<i>ABCB1</i>		Carbamazepine	3,293 patients with epilepsy. Meta analysis	Pharmacokinetics/ Efficacy	The T allele was associated with lower concentrations, lower absorption, and resistance to the drug activity.	0.004	T		4
<i>ABCB1</i>		Carbamazepine	2,126 patients with epilepsy. Meta-analysis	Efficacy	The T allele was associated to decreased plasma concentrations of the drug.	<0.05	G		5
<i>ABCB1</i>		Agomelatine	28 healthy volunteers (Spain)	Pharmacokinetics	The TT genotype was associated with lower concentrations or lower absorption of the drug.	0.047	G		6
<i>ABCB1</i>		All antiepileptic drugs	8,716 patients with epilepsy, 4,037 drug-resistant epilepsy patients and 4,679 drug-responsive patients. Meta analysis	Efficacy	The T allele was associated with higher risk of drug resistance in the overall population and in Caucasians.	0.006	G		7
<i>ABCB1</i>		Carbamazepine	In vitro	Impact of T allele on the sensitivity, intracellular accumulation, and transepithelial permeability of antiepileptic drugs	The recombinant T allele_cells showed higher resistance to carbamazepine compared with C allele_cells in the cytotoxicity assay. The intracellular accumulation of carbamazepine was significantly decreased in cells transfecting with recombinant T allele when compared with recombinant C allele_cells.	0.01	G		8
<i>ABCB1</i>		Carbamazepine	210 patients with epilepsy (China)	Pharmacokinetics	The GG genotype was associated with increased concentrations of carbamazepine relative to the AG genotype.	0.001	G		9
<i>ABCB1</i>	rs10248420	All antidepressants	256 patients with epilepsy (Europe)	Efficacy	The G allele was associated with increased likelihood of remission when treated with amitriptyline, citalopram, paroxetine or venlafaxine relative to the A allele.	0.0095	G	G	11
<i>ABCB1</i>		Olanzapine	80 healthy volunteers (Spain)	Efficacy	The A allele was associated with decreased drug response compared to the G allele	0.047	G		26
<i>ABCB1</i>	rs1128503	All antiepileptic drugs	90 patients with epilepsy (USA)	Pharmacokinetics	AA and AG genotypes were associated with increased clearance of carbamazepine relative to the GG genotype.	0.036	G	G	12
<i>ABCB1</i>		Lamotrigine	222 patients with epilepsy (Croatia)	Pharmacokinetics	The genotype CC was associated with higher lamotrigine concentrations compared to CT and TT genotypes.	0.021	G		22
<i>ABCB1</i>		Carbamazepine	2,126 patients with epilepsy. Meta-analysis	Efficacy	The CC genotype was associated with lower resistance to carbamazepine.	0.03	G		5
<i>ABCB1</i>	rs2235015	All antidepressants	339 patients with depression (European)	Efficacy	The A allele was associated with higher remission for P-glycoprotein antidepressants, citalopram, paroxetine, amitriptyline, and venlafaxine, relative to the C allele.	0.025	A	A	11



Gene	Polymorphism	Drug	Study participants	Effect		P-value	Expected risk allele in the publication	Risk allele for birth weight	Reference
ABCB1		All antidepressants	73 patients with depressive disorder (Germany)	Efficacy	The A allele was associated with increased likelihood of remission when treated with amitriptyline, citalopram, paroxetine or venlafaxine, relative to the C allele.	0.030	A		17
ABCB1	rs9282564	Paroxetine	71 psychiatric patients (Switzerland)	Efficacy	The G allele was associated with greater clinical response.	0.043	G	G	28
ABCB1	rs10245483	All antidepressants	683 patients with major depressive disorder (multisite)	Efficacy	The T allele was associated with less remission.	0.001	G	G	29
ABCC1	rs875740	All antiepileptic drugs	199 patients from the Mayo Clinic Bipolar Disorder Biobank GWAS (USA)	Efficacy	The C allele was associated with better treatment response.	0.0089	C	C	30
ABCC1	rs212090	Clozapine	137 medicated patients (Australia)	Adverse effects	The A allele was associated with higher diastolic blood pressure (adverse effect)	0.01	A	A	31
ABCC1		All antidepressants	148 patients with major depressive disorder (Australia)	Efficacy	The A allele was included in the pharmacogenetic guide group and associated with greater remission	0.0001	A		32
ABCC2	rs717620	All antiepileptic drugs	537 patients with epilepsy (217 drug resistant patients and 320 drug responders) (China)	Efficacy	The TT genotype was associated with drug resistance	0.001	C	C	33
ABCC2		All antiepileptic drugs	4,300 patients with epilepsy (2,261 drug-resistant patients and 2,039 drug-responsive patients). Meta-analysis	Efficacy	The T allele was associated with drug resistance	0.0006	C		34
ABCC2		All antiepileptic drugs	254 patients with epilepsy (104 drug-resistant and 150 drug-responsive) (China)	Efficacy	The TT genotype was associated with drug resistance, relative to the CC genotype	0.001	C		35
ABCC2		All antiepileptic drugs	1,842 patients with epilepsy. Meta-analysis	Efficacy	The T allele was associated with drug resistance.	0.002	C		36
ABCC2	rs2273697	All antiepileptic drugs	90 patients with epilepsy (USA)	Pharmacokinetics	AA and AG genotypes were associated with higher drug clearance relative to the GG genotype.	<0.05	G	G	12
ABCC2		All antiepileptic drugs	453 patients with epilepsy (China)	Efficacy	The A allele was associated with drug resistance.	0.001	G		37
ABCC2	rs3740066	All antiepileptic drugs	90 patients with epilepsy (USA)	Pharmacokinetics	The G allele was associated with lower carbamazepine-10, 11-epoxide (metabolite): carbamazepine ratio.	0.008	C	C	12
ABCC2		All antiepileptic drugs	537 patients with epilepsy (217 drug resistant patients and 320 drug responders) (China)	Efficacy	CT and TT genotypes were associated with drug resistance relative to CC genotype.	0.038	C		33
ABCC2		No drug	In vitro study	In vitro function of the transporter	The T allele was associated with a decreased function of the transporter.	0.017	C		38

Gene	Polymorphism	Drug	Study participants	Effect		P-value	Expected risk allele in the publication	Risk allele for birth weight	Reference
ABCG2	rs2231142	Lamotrigine	112 patients with epilepsy (China)	Pharmacokinetics	The TT genotype was associated with increased concentrations of lamotrigine relative to GG and GT genotypes.	0.015	T	T	39
ABCG2		Lamotrigine	140 patients with epilepsy (China)	Pharmacokinetics	CA and AA genotypes were associated with higher concentrations of lamotrigine relative to the CC genotype.	<0.05	T		40
ABCG2	rs3114020	Lamotrigine	140 patients with epilepsy (China)	Pharmacokinetics	CC and CT genotypes were associated with increased concentrations of lamotrigine relative to the TT genotype.	0.01	C	C	40


548 **Supplemental Table 3. STROBE checklist for cohort studies**  
549

	Item No	Recommendation	Page No
Title and abstract			
Title and abstract	1	(a) Indicate the study’s design with a commonly used term in the title or the abstract	1
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	3-4
Introduction			
Background/ rationale	2	Explain the scientific background and rationale for the investigation being reported	6-7
Objectives	3	State specific objectives, including any pre-specified hypotheses	6-7
Methods			
Study design	4	Present key elements of study design early in the paper	6
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	8
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up	8-9
		(b) For matched studies, give matching criteria and number of exposed and unexposed	-
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	9-11
Data sources/ measurement	8	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	8-11
Bias	9	Describe any efforts to address potential sources of bias	9-11
Study size	10	Explain how the study size was arrived at	Fig.1
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	10
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	10-11
		(b) Describe any methods used to examine subgroups and interactions	10-11
		(c) Explain how missing data were addressed	-
		(d) If applicable, explain how loss to follow-up was addressed	-
		(e) Describe any sensitivity analyses	11
Results			
Participants	13*	(a) Report numbers of individuals at each stage of study—e.g. numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analyzed	Fig. 1
		(b) Give reasons for non-participation at each stage	
		(c) Consider use of a flow diagram	
Descriptive data	14*	(a) Give characteristics of study participants (e.g. demographic, clinical, social) and information on exposures and potential confounders	11, Table 1
		(b) Indicate number of participants with missing data for each variable of interest	-
		(c) Summarize follow-up time (e.g., average and total amount)	-
Outcome data	15	Report numbers of outcome events or summary measures over time	14-18
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (e.g., 95% confidence interval). Make clear which confounders were adjusted for and why they were included	14-18 Figures 2,3
		(b) Report category boundaries when continuous variables were categorized	14-18 Figures 2,3
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	-
Other analyses	17	Report other analyses done—e.g. analyses of subgroups and interactions, and sensitivity analyses	18, Suppleme ntal figures 2-5
Discussion			
Key results	18	Summarize key results with reference to study objectives	19
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	20
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	19-20
Generalizability	21	Discuss the generalizability (external validity) of the study results	20
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	23


550

## SUPPLEMENTAL RESULTS

**Supplemental Figure 1.** Flow chart of the systematic literature review of genetic variants on placental efflux transporters.




556 **Supplemental Figure 2.** Differences in birth weight associated with pregnancy use of  
557 antiseizure drugs due to *ABCC2* individual genetic variants in the offspring.




558

559 **Supplemental Figure 3.** Differences in birth weight associated with pregnancy use of  
560 antiepileptic drugs due to *ABCB1* individual genetic variants in the mother.  
561




562  
563  
564

**Supplemental Figure 4.** Differences in birth weight associated with pregnancy use of antidepressant medication and placental transporter genetic scores in the offspring.



565  
566

**Supplemental Figure 5.** Differences in birth weight associated with pregnancy use of antidepressant medication and placental transporter genetic scores in the mother.





## SUPPLEMENTAL REFERENCES

1. Hung C-C, Jen Tai J, Kao P-J, Lin M-S, Liou H-H. Association of polymorphisms in NR1I2 and ABCB1 genes with epilepsy treatment responses. *Pharmacogenomics*. 2007;8: 1151–1158. doi:10.2217/14622416.8.9.1151
2. Kwan P, Baum L, Wong V, Ng PW, Lui CHT, Sin NC, et al. Association between ABCB1 C3435T polymorphism and drug-resistant epilepsy in Han Chinese. *Epilepsy Behav*. 2007;11: 112–117. doi:10.1016/j.yebeh.2007.04.013
3. Shaheen U, Prasad DKV, Sharma V, Suryaprabha T, Ahuja YR, Jyothy A, et al. Significance of MDR1 gene polymorphism C3435T in predicting drug response in epilepsy. *Epilepsy Res*. 2014;108: 251–256. doi:10.1016/j.eplepsyres.2013.11.009
4. Zhang M-L, Chen X-L, Bai Z-F, Zhao X, Li W-X, Wang X-Y, et al. ABCB1 c.3435C > T and EPHX1 c.416A > G polymorphisms influence plasma carbamazepine concentration, metabolism, and pharmacoresistance in epileptic patients. *Gene*. 2021;805: 145907. doi:10.1016/j.gene.2021.145907
5. Fan Y-X, Zhang Z, Meng J-R, Yin S-J, Wang P, Zhou T, et al. Association of ABCB1 polymorphisms with carbamazepine metabolism and resistance in epilepsy: A meta-analysis. *Epilepsy Res*. 2021;177: 106785. doi:10.1016/j.eplepsyres.2021.106785
6. Saiz-Rodríguez M, Ochoa D, Belmonte C, Román M, Vieira de Lara D, Zubiaur P, et al. Polymorphisms in CYP1A2, CYP2C9 and ABCB1 affect agomelatine pharmacokinetics. *J Psychopharmacol*. 2019;33: 522–531. doi:10.1177/0269881119827959
7. Li M, Tan J, Yang X, Su L, Xie J, Liang B, et al. The ABCB1-C3435T polymorphism likely acts as a risk factor for resistance to antiepileptic drugs. *Epilepsy Res*. 2014;108: 1052–1067. doi:10.1016/j.eplepsyres.2014.03.019

- 592 8. Shen X-M, Cheng J. Effects ofMDR1(C3435T) polymorphism on resistance,  
593 uptake, and efflux to antiepileptic drugs. DNA Cell Biol. 2019;38: 250–255.  
594 doi:10.1089/dna.2018.4553
- 595 9. Zhu X, Yun W, Sun X, Qiu F, Zhao L, Guo Y. Effects of major transporter and  
596 metabolizing enzyme gene polymorphisms on carbamazepine metabolism in Chinese  
597 patients with epilepsy. Pharmacogenomics. 2014;15: 1867–1879.  
598 doi:10.2217/pgs.14.142
- 599 10. Huang X, Yu T, Li X, Cao Y, Li X, Liu B, et al. ABCB6, ABCB1 and ABCG1 genetic  
600 polymorphisms and antidepressant response of SSRIs in Chinese depressive patients.  
601 Pharmacogenomics. 2013;14: 1723–1730. doi:10.2217/pgs.13.151
- 602 11. Uhr M, Tontsch A, Namendorf C, Ripke S, Lucae S, Ising M, et al. Polymorphisms  
603 in the drug transporter gene ABCB1 predict antidepressant treatment response in  
604 depression. Neuron. 2008;57: 203–209. doi:10.1016/j.neuron.2007.11.017
- 605 12. Puranik YG, Birnbaum AK, Marino SE, Ahmed G, Cloyd JC, Remmel RP, et al.  
606 Association of carbamazepine major metabolism and transport pathway gene  
607 polymorphisms and pharmacokinetics in patients with epilepsy. Pharmacogenomics.  
608 2013;14: 35–45. doi:10.2217/pgs.12.180
- 609 13. Lee S-T, Ryu S, Kim S-R, Kim M-J, Kim S, Kim J-W, et al. Association study of  
610 27 annotated genes for clozapine pharmacogenetics: Validation of preexisting studies  
611 and identification of a new candidate gene, ABCB1, for treatment response. J Clin  
612 Psychopharmacol. 2012;32: 441–448. doi:10.1097/jcp.0b013e31825ac35c
- 613 14. Breitenstein B, Brückl TM, Ising M, Müller-Myhsok B, Holsboer F, Czamara D.  
614 ABCB1gene variants and antidepressant treatment outcome: A meta-analysis. Am J  
615 Med Genet B Neuropsychiatr Genet. 2015;168: 274–283. doi:10.1002/ajmg.b.32309

- 616 15. de Klerk OL, Nolte IM, Bet PM, Bosker FJ, Snieder H, den Boer JA, et al. ABCB1  
617 gene variants influence tolerance to selective serotonin reuptake inhibitors in a large  
618 sample of Dutch cases with major depressive disorder. *Pharmacogenomics J.* 2013;13:  
619 349–353. doi:10.1038/tpj.2012.16
- 620 16. Sarginson JE, Lazzeroni LC, Ryan HS, Ershoff BD, Schatzberg AF, Murphy GM.  
621 ABCB1 (MDR1) polymorphisms and antidepressant response in geriatric depression.  
622 *Pharmacogenet Genomics.* 2010;20: 467–475. doi:10.1097/fpc.0b013e32833b593a
- 623 17. Breitenstein B, Scheuer S, Brückl TM, Meyer J, Ising M, Uhr M, et al. Association  
624 of ABCB1 gene variants, plasma antidepressant concentration, and treatment response:  
625 Results from a randomized clinical study. *J Psychiatr Res.* 2016;73: 86–95.  
626 doi:10.1016/j.jpsychires.2015.11.010
- 627 18. Gassó P, Rodríguez N, Mas S, Pagerols M, Blázquez A, Plana MT, et al. Effect  
628 of CYP2D6, CYP2C9 and ABCB1 genotypes on fluoxetine plasma concentrations and  
629 clinical improvement in children and adolescent patients. *Pharmacogenomics J.*  
630 2014;14: 457–462. doi:10.1038/tpj.2014.12
- 631 19. Glauser TA, Holland K, O'Brien VP, Keddache M, Martin LJ, Clark PO, et al.  
632 Pharmacogenetics of antiepileptic drug efficacy in childhood absence epilepsy: CAE  
633 Pharmacogenetics. *Ann Neurol.* 2017;81: 444–453. doi:10.1002/ana.24886
- 634 20. Kato M, Fukuda T, Serretti A, Wakeno M, Okugawa G, Ikenaga Y, et al. ABCB1  
635 (MDR1) gene polymorphisms are associated with the clinical response to paroxetine in  
636 patients with major depressive disorder. *Progress in Neuro-Psychopharmacology and*  
637 *Biological Psychiatry.* 2008;32: 398–404. doi:10.1016/j.pnpbp.2007.09.003
- 638 21. Mittal B, Kumari R, Lakhan R, Garg RK, Kalita J, Misra UK. Pharmacogenomic  
639 association study on the role of drug metabolizing, drug transporters and drug target  
640 gene polymorphisms in drug-resistant epilepsy in a north Indian population. *Indian J Hum*  
641 *Genet.* 2011;17: 32. doi:10.4103/0971-6866.80357

- 642 22. Lovrić M, Božina N, Hajnšek S, Kuzman MR, Sporiš D, Lalić Z, et al. Association  
643 between lamotrigine concentrations and ABCB1 polymorphisms in patients with  
644 epilepsy. *Ther Drug Monit.* 2012;34: 518–525. doi:10.1097/ftd.0b013e31826517c6
- 645 23. Rafaniello C, Sessa M, Bernardi FF, Pozzi M, Cheli S, Cattaneo D, et al. The  
646 predictive value of ABCB1, ABCG2, CYP3A4/5 and CYP2D6 polymorphisms for  
647 risperidone and aripiprazole plasma concentrations and the occurrence of adverse drug  
648 reactions. *Pharmacogenomics J.* 2018;18: 422–430. doi:10.1038/tpj.2017.38
- 649 24. Vijayan NN, Mathew A, Balan S, Natarajan C, Nair CM, Allencherry PM, et al.  
650 Antipsychotic drug dosage and therapeutic response in schizophrenia is influenced by  
651 ABCB1 genotypes: a study from a south Indian perspective. *Pharmacogenomics.*  
652 2012;13: 1119–1127. doi:10.2217/pgs.12.86
- 653 25. Subenthiran S, Abdullah NR, Muniandy PK, Joseph JP, Cheong KC, Ismail Z, et  
654 al. G2677T polymorphism can predict treatment outcome of Malaysians with complex  
655 partial seizures being treated with Carbamazepine. *Genet Mol Res.* 2013;12: 5937–  
656 5944. doi:10.4238/2013.november.26.3
- 657 26. Zubiaur P, Soria-Chacartegui P, Koller D, Navares-Gómez M, Ochoa D,  
658 Almenara S, et al. Impact of polymorphisms in transporter and metabolizing enzyme  
659 genes on olanzapine pharmacokinetics and safety in healthy volunteers. *Biomed*  
660 *Pharmacother.* 2021;133: 111087. doi:10.1016/j.biopha.2020.111087
- 661 27. Bet PM, Verbeek EC, Milaneschi Y, Straver DBM, Uithuisje T, Bevoa MR, et al.  
662 A common polymorphism in the ABCB1 gene is associated with side effects of PGP-  
663 dependent antidepressants in a large naturalistic Dutch cohort. *Pharmacogenomics J.*  
664 2016;16: 202–208. doi:10.1038/tpj.2015.38
- 665 28. Gex-Fabry M, Eap CB, Oneda B, Gervasoni N, Aubry J-M, Bondolfi G, et al.  
666 CYP2D6 and ABCB1 genetic variability: Influence on paroxetine plasma level and

667 therapeutic response. *Ther Drug Monit.* 2008;30: 474–482.  
668 doi:10.1097/ftd.0b013e31817d6f5d

669 29. Schatzberg AF, DeBattista C, Lazzeroni LC, Etkin A, Murphy GM Jr, Williams LM.  
670 ABCB1 genetic effects on antidepressant outcomes: A report from the iSPOT-D trial. *Am*  
671 *J Psychiatry.* 2015;172: 751–759. doi:10.1176/appi.ajp.2015.14050680

672 30. Ho AM-C, Coombes BJ, Nguyen TTL, Liu D, McElroy SL, Singh B, et al. Mood-  
673 stabilizing antiepileptic treatment response in bipolar disorder: A genome-wide  
674 association study. *Clin Pharmacol Ther.* 2020;108: 1233–1242. doi:10.1002/cpt.1982

675 31. Piatkov I, Caetano D, Assur Y, Lau SL, Jones T, Boyages SC, et al. ABCB1 and  
676 ABCC1 single-nucleotide polymorphisms in patients treated with clozapine.  
677 *Pharmgenomics Pers Med.* 2017;10: 235–242. doi:10.2147/pgpm.s142314

678 32. Singh AB. Improved antidepressant remission in major depression via a  
679 pharmacokinetic pathway polygene pharmacogenetic report. *Clin Psychopharmacol*  
680 *Neurosci.* 2015;13: 150–156. doi:10.9758/cpn.2015.13.2.150

681 33. Qu J, Zhou B-T, Yin J-Y, Xu X-J, Zhao Y-C, Lei G-H, et al. ABCC2 polymorphisms  
682 and haplotype are associated with drug resistance in Chinese epileptic patients: ABCC2  
683 polymorphisms and epilepsy drug resistance. *CNS Neurosci Ther.* 2012;18: 647–651.  
684 doi:10.1111/j.1755-5949.2012.00336.x

685 34. Qian L, Fang S, Yan Y-L, Zeng S-S, Xu Z-J, Gong Z-C. The ABCC2 c.-24C > T  
686 polymorphism increases the risk of resistance to antiepileptic drugs: A meta-analysis. *J*  
687 *Clin Neurosci.* 2017;37: 6–14. doi:10.1016/j.jocn.2016.10.014

688 35. Xue T, Lu ZN. Association between the polymorphisms in the ATP-binding  
689 cassette genes ABCB1 and ABCC2 and the risk of drug-resistant epilepsy in a Chinese  
690 Han population. *Genet Mol Res.* 2016;15. doi:10.4238/gmr15048752

691 36. Grover S, Kukreti R. A systematic review and meta-analysis of the role  
692 of ABCC2 variants on drug response in patients with epilepsy. *Epilepsia*. 2013;54: 936–  
693 945. doi:10.1111/epi.12132

694 37. Ma C-L, Wu X-Y, Zheng J, Wu Z-Y, Hong Z, Zhong M-K. Association of SCN1A,  
695 SCN2A and ABCC2 gene polymorphisms with the response to antiepileptic drugs in  
696 Chinese Han patients with epilepsy. *Pharmacogenomics*. 2014;15: 1323–1336.  
697 doi:10.2217/pgs.14.89

698 38. Laechelt S, Turrini E, Ruehmkoef A, Siegmund W, Cascorbi I, Haenisch S. Impact  
699 of ABCC2 haplotypes on transcriptional and posttranscriptional gene regulation and  
700 function. *Pharmacogenomics J*. 2011;11: 25–34. doi:10.1038/tpj.2010.20

701 39. Shen C-H, Zhang Y-X, Lu R-Y, Jin B, Wang S, Liu Z-R, et al. Specific OCT1 and  
702 ABCG2 polymorphisms are associated with Lamotrigine concentrations in Chinese  
703 patients with epilepsy. *Epilepsy Res*. 2016;127: 186–190.  
704 doi:10.1016/j.epilepsyres.2016.09.004

705 40. Zhou Y, Wang X, Li H, Zhang J, Chen Z, Xie W, et al. Polymorphisms of ABCG2,  
706 ABCB1 and HNF4 $\alpha$  are associated with Lamotrigine trough concentrations in epilepsy  
707 patients. *Drug Metab Pharmacokinet*. 2015;30: 282–287.  
708 doi:10.1016/j.dmpk.2015.05.002

709